| Literature DB >> 29330676 |
Laura C Falzon1,2, Isabel Lechner3, Ilias Chantziaras4, Lucie Collineau5, Aurélie Courcoul6, Maria-Eleni Filippitzi4, Riikka Laukkanen-Ninios7, Carole Peroz8, Jorge Pinto Ferreira5, Merel Postma4, Pia G Prestmo9, Clare J Phythian10, Eleonora Sarno11, Gerty Vanantwerpen12, Timothée Vergne13,14,15, Douglas J C Grindlay16, Marnie L Brennan17.
Abstract
Having gained momentum in the last decade, the One Health initiative promotes a holistic approach to address complex global health issues. Before recommending its adoption to stakeholders, however, it is paramount to first compile quantitative evidence of the benefit of such an approach. The aim of this scoping review was to identify and summarize primary research that describes monetary and non-monetary outcomes following adoption of a One Health approach. An extensive literature search yielded a total of 42,167 references, of which 85 were included in the final analysis. The top two biotic health issues addressed in these studies were rabies and malaria; the top abiotic health issue was air pollution. Most studies described collaborations between human and animal (n = 42), or human and environmental disciplines (n = 41); commonly reported interventions included vector control and animal vaccination. Monetary outcomes were commonly expressed as cost-benefit or cost-utility ratios; non-monetary outcomes were described using disease frequency or disease burden measurements. The majority of the studies reported positive or partially positive outcomes. This paper illustrates the variety of health challenges that can be addressed using a One Health approach, and provides tangible quantitative measures that can be used to evaluate future implementations of the One Health approach.Entities:
Keywords: Endemic and emerging infectious diseases; Non-communicable diseases; One Medicine; Scoping review; Systematic evidence; Transdisciplinarity; Zoonoses
Mesh:
Year: 2018 PMID: 29330676 PMCID: PMC6003973 DOI: 10.1007/s10393-017-1310-5
Source DB: PubMed Journal: Ecohealth ISSN: 1612-9202 Impact factor: 3.184
Fig. 1Flow of methodological activities and information through the different phases of a scoping review on the quantitative outcome of a One Health approach to address complex global health challenges, as described by the PRISMA guidelines (Moher et al. 2009). aKeywords reported in Rushton 2009; Häsler et al. 2012; Minutes of the Expert Workshop 2013. bBased on a recommendation that three to five databases are considered sufficient (Young et al. 2014). cTexts available between 1980 and 2014. dTexts available between 1946 and 2014. eTexts available between 1910 and 2014. fPart of the National Institute for Health Research Centre for Reviews and Dissemination, UK. gRefworks© (ProQuest, LLC, Cambridge Information Group; Betheseda, MD, USA). hCommunity of Practice in Ecosystem Approaches to Health—Canada.
A List of the Search Terms Used in Four Electronic Databases (MEDLINE, Embase, NHS EED, and CAB Abstracts) to Identify References that Describe a Quantitative Outcome when Using a One Health Approach to Address Complex Global Health Challenges.
| ((animal AND human) OR (animals and human) OR (animal AND humans) OR (animals AND humans) OR (human AND environment) OR (humans AND environment) OR (animal AND environment) OR (animals AND environment) OR “animal to human” OR “human to animal” OR “social-ecological” OR “socio-ecological” OR “One Health” OR “Ecohealth” OR “One World” OR “One Medicine” OR (ecosystem AND health) OR (holistic AND health) OR (veterinary AND human medicine) OR interdisciplinary OR multidisciplinary OR transdisciplinary OR “cross sector” OR “inter sector” OR “trans sector” OR zoonos* OR zoonotic OR “veterinary public health” OR “VPH” OR “farm to fork” OR “stable to table” OR “value chain”) |
| AND |
| (DALY* OR HALY* OR QALY* OR “disability adjusted life year” OR “disability adjusted life years” OR “health adjusted life year” OR “health adjusted life years” OR “quality adjusted life year” OR “quality adjusted life years” OR “expected quality adjusted life year” OR “expected quality adjusted life years” OR “opportunity cost” OR “opportunity costs” OR “cost benefit” OR “cost benefits” OR “cost analys*” OR “cost assessment” OR “cost effectiveness” OR “cost utility” OR “cost utilities” OR profit* OR “cost allocation” OR “cost benefit analys*” OR “cost control” OR “cost controls” OR “cost saving” OR “cost savings” OR “costs savings” OR “cost of illness” OR “costs of illness” OR “cost of disease” OR “costs of disease” OR “cost of intervention” OR “costs of intervention” OR “cost sharing” OR “costs sharing” OR “health care cost” OR “health care costs” OR “health care expenditure” OR “health care expenditures” OR “value of life” OR “societal benefit*” OR “economic evaluation” OR “economic analys*” OR “economic assessment” OR “health economics” OR “resource allocation” OR “cost avoidance” OR “costs avoidance” OR “loss avoidance” OR “losses avoidance”) |
Fig. 2A world map indicating the number of studies conducted in different countries and included in a scoping review on the quantitative outcome of a One Health approach to address complex global health challenges.
Fig. 3Abiotic and biotic health issues described, per continent, in a scoping review on the quantitative outcome of a One Health approach to address complex global health challenges.
Fig. 4Abiotic and biotic health issues described in a scoping review on the quantitative outcome of a One Health approach to study complex health challenges.
Fig. 5Proportion of studies that described monetary, non-monetary, or both outcomes to assess the top five diseases included in a scoping review on the quantitative outcome of a One Health approach to address complex global health challenges.
An Overview of the Type and Value of Quantitative Outcomes Featuring in Those Studies that Described One Health Interventions to Address Rabies Included in this Scoping Review.
| References | Geographical location | Intervention | Type of quantitative outcome described | Outcome reported |
|---|---|---|---|---|
|
| ||||
| Bögel and Meslin ( | Developing countries | Combined dog vaccination and human PEPa | Cost efficiency | Cost-efficient in 5 years |
| Fishbein et al. ( | Philippines | One-year dog vaccination campaign | Time to recoup costs | 4.1–11.0 years |
| Fitzpatrick et al. ( | Tanzania | Annual dog vaccination campaigns (at different vaccination coverage) | Number of deaths averted | 0.6–2.0 |
| Percentage of deaths averted | 8.3–39.3% | |||
| Cost-effectiveness | Cost-effective to very cost-effective | |||
| Häsler et al. ( | Sri Lanka | Dog vaccination and other control interventions | DALYsb averted | 738 |
| Animal welfare impact score | Improved | |||
| Program costs | US$ 1.03 million | |||
| Pinto et al. ( | Brazil | Dog vaccination (vs. human PEPa) | Cost comparison | Costs 9.2–20.2 lower (in Brazilian Real) |
| Tenzin and Ward ( | Bhutan | Combined dog vaccination and human PEPa (vs. human PEPa only) | Cost savings | US$ 0.09 million saved after 6 years |
| Townsend et al. ( | Bali | Comprehensive high coverage dog vaccination | Human lives saved over 10 years | 550 |
| Money saved over 10 years | US$ 15 million | |||
| Zinsstag et al. ( | Chad | One-year dog vaccination campaign | Cost per death averted | US$ 596 |
| Time to recoup costs | 5.9 years | |||
|
| ||||
| Aubert ( | France | Wildlife vaccination (vs. fox depopulation) | Cost–benefit analysis | Beneficial after 4th year |
| Ministère de la Santé et de la Protection Sociale Française ( | France | Evaluation of oral vaccination programs in wildlife | Cost–benefit analysis | Beneficial in 10–12 years (less for some departments) |
| Shwiff et al. ( | Canada | Rabies control program including fox vaccination | Benefit–cost ratio | 0.49–1.36 |
| Cost savings | US$ 35.48–98.41 million | |||
| Shwiff et al. ( | Canada | Rabies control programs including raccoon vaccination | Benefit–cost ratio | 0.96–1.55 |
| Cost savings | US$ 46.70–52.93 million | |||
| Uhaa et al. ( | USA | Administration of oral vaccines to raccoons | Benefit–cost ratio | 2.21–6.80 |
| Cost savings | US $1.95 million |
aPEP post-exposure prophylaxis.
bDALYs disability-adjusted life years.
An Overview of the Type and Value of Quantitative Outcomes Featured in Those Studies that Described One Health Interventions to Address Salmonellosis Included in this Scoping Review.
| References | Geographical location | Intervention | Type of quantitative outcome described | Outcome reported |
|---|---|---|---|---|
| Goldbach and Alban ( | Denmark | Hot water decontamination of pig carcasses | Net present value | 3.5 million Euro over 15 years |
| Kangas et al. ( | Finland | Salmonella control policies in broiler production | Benefit–cost ratio | 0.04–21.25 |
| Korsgaard et al. ( | Denmark | Salmonella control programs in egg production | Number of human cases averted | 10,200 (95% CI: 8100–12,400) |
| Societal costs saved | 23.3 million Euro (95% CI: 16.3– 34.9) | |||
| Cost–benefit ratio | 0.5 | |||
| Miller et al. ( | USA | Pig vaccination | Reduction in human cases | 60% |
| Benefit–cost ratio | Less than 1 | |||
| Pig carcass rinsing at various water temperatures | Benefit–cost ratio | Greater than 1 | ||
| Persson and Jendteg ( | England, Wales and Sweden | Use of competitive exclusion in poultry production | Costs of illness saved | Up to 12.6 million GBP |
| Romero-Barrios et al. ( | European Union | Interventions on pig farms and during pig slaughter | Risk reduction | Up to 90% risk reduction |
| Wegener et al. ( | Denmark | Salmonella control programs in pig and poultry production | Costs saved | US $25.5 million |
An Overview of the Type and Value of Quantitative Outcomes Featured in Those Studies that Described One Health Interventions to Address Campylobacteriosis Included in this Scoping Review.
| References | Geographical location | Intervention | Type of quantitative outcome described | Outcome reported |
|---|---|---|---|---|
| Gellynck et al. ( | Belgium | Decontamination of poultry carcasses with electrolyzed oxidizing water | Cost–benefit ratio | 17.66 |
| Decontamination of poultry carcasses with lactic acid | 4.06 | |||
| Phage therapy used on chicken farms | 2.54 | |||
| Havelaar et al. ( | The Netherlands | Strict hygienic measures on chicken farms | Cost-effectiveness based on a cost–utility ratioa ≤ Euro 50,000/DALYsb | Cost-effective |
| Reduced fecal leakage during carcass processing | Cost-effective | |||
| Chemical decontamination of poultry carcasses | Cost-effective | |||
| Jensen and Jensen ( | European Union | Vaccination of chicks | Cost neutralization | 1.65 Euro per vaccine dose |
| Lake et al. ( | New Zealand | Poultry slaughterhouse improvements (e.g., new evisceration machines) | Cost per DALYsb saved | NZ$ 1200 |
| Continuous chemical treatment of poultry carcass | NZ$ 1700 | |||
| Phage-based controls on chicken farms | NZ$ 3000 | |||
| Mangen et al. ( | The Netherlands | Phage therapy used on chicken farms | Cost-effectiveness based on a cost–utility ratioa ≤ 100,000 Euro/DALYsb | Cost-effective |
| Romero-Barrios et al. ( | European Union | Application of fly screens in indoor poultry flocks | Risk reduction | 60% |
| Treating or freezing broiler carcasses | 87–98% |
aCost–utility ratio is described as the ratio of the net cost of intervention to averted disease burden in DALYs.
bDALYs disability-adjusted life years.
An Overview of the Type and Value of Quantitative Outcomes Featuring in Those Studies that Described One Health Interventions to Address Malaria Included in this Scoping Review.
| References | Geographical location | Intervention | Type of quantitative outcome described | Outcome reported |
|---|---|---|---|---|
| Aikins et al. ( | Gambia | Use of ITNa | Cost-effectiveness per death averted | US$ 471 |
| Cost-effectiveness per discounted life years gained | US$ 31.53 | |||
| Akhavan et al. ( | Brazil | National malaria control program including vector control | Cost-effectiveness per life saved | US$ 2672 |
| Cost-effectiveness per DALYsb averted | US$ 69 | |||
| Gatton and Cheng ( | Australia | ITNa and chemotherapy | Disease transmission | No transmission possible |
| Goodman et al. ( | Low-income country in sub-Saharan Africa | Provision of bed nets | Cost-effectiveness per DALYsb averted | US$ 19–85 |
| Insecticide treatment of existing bed nets | US$ 4–10 | |||
| Goodman et al. ( | South Africa | ITNa (vs. residual house spraying) | Effectiveness (adjusted rate ratio based on number of cases) | 0.69 |
| Cost per case averted | US$ 16 | |||
| Cost per death averted | US$ 1696 | |||
| Mueller et al. ( | Togo | Three-year ITNa campaign | Number of deaths averted | 6285 |
| Number of cases averted | 1.2 million | |||
| Cost per death averted | US$ 635 | |||
| Cost per DALYsb averted | US$ 16.39 | |||
| Mulligan et al. ( | Tanzania | ITNa voucher program | Number of child deaths averted | 12,039 |
| Cost per child death averted | US$ 873 | |||
| Pulkki-Brännström et al. ( | Not specified | Long-lasting ITNa (vs. conventional ITNa) | Child deaths averted | 30,800 |
| DALYsb averted | 1.02 million | |||
| Cost per DALYsb averted | US$ 16.8 | |||
| Cost-effectiveness | Cost-effective if priced at no more than US$ 1.5 above conventional ITNa | |||
| Riedel et al. ( | Zambia | Bed nets | Odds of parasitaemia | 40% less (12–60%) |
| Smithuis et al. ( | Myanmar | ITNa (vs. early diagnosis and effective treatment) | Cost per DALYsb averted | US$ 51 |
| Yhdego and Majura ( | Tanzania | Comparison of two vector control programs: engineering vs. use of larvicides and insecticides | Program effectiveness | 97 vs. 75% |
| Cost-effectiveness | Tshs 2.8 million vs. Tshs 10.5 million |
aITN insecticide-treated bed nets.
bDALYs disability-adjusted life years.
An Overview of the Type and Value of Quantitative Outcomes Featured in Those Studies that Described One Health Interventions to Address Dengue Included in this Scoping Review.
| References | Geographical location | Intervention | Quantitative outcome described | Values reported |
|---|---|---|---|---|
| Díaz ( | Cuba | Integrated surveillance system | Detection of febrile cases | Increased |
| McConnell and Gubler ( | Puerto Rico | Control of vector breeding sites | Cost-effectiveness | Cost-effective if dengue transmission is reduced by 50% and intervention costs less than US$ 2.50 per person |
| Ocampoa et al. ( | Colombia | Identification and spraying of vector breeding sites | Rate ratio of human incidence | 0.19 (95% CI 0.12–0.30) compared to control area |
| Orellano and Pedroni ( | Argentina | Fumigation of vectors | Net present value | I$ 196,879 |
| Cost–benefit analysis | Beneficial when more than 1363 cases of dengue and at least 1 case of dengue hemorrhagic fever are averted | |||
| Suaya et al. ( | Cambodia | Annual targeted larvicidal campaigns | Cost per DALYsa saved (public perspective) | US$ 313 |
| Cost per DALYsa saved (societal perspective) | US$ 37 | |||
| Tsunoda et al. ( | Vietnam | Use of insecticide-treated nets to cover water reservoirs | Human seroprevalence | 62.2% (vs. 74.6% in control area) |
| Addition of insecticide to other water containers |
aDALYs disability-adjusted life years.